New treatments for ALS are only possible because of the people who participate in and conduct clinical trials. As the number of ALS trials continues to increase, the number of people with ALS who enroll in studies and the capacity of trial sites will need to increase as well.

Currently, many people living with ALS who want to participate in clinical trials are unaware of opportunities or lack access to local trial sites. In addition, many trial sites do not have the infrastructure to accommodate significantly more participants and/or additional trial protocols.  

Our Trial Capacity Awards provide up to $400,000 over 4 years to help eliminate barriers to trial participation, especially those impacting currently underserved populations, and help increase the number and diversity of people living with ALS who have the opportunity to participate. These awards also support efforts to improve speed and efficiency at both established and emerging clinical trial sites across the U.S.

Trial Capacity Award Recipients

We need to understand how drugs work in the entire population, and then just out of fairness, everybody should be given opportunities.”
Terry Heiman-Patterson, M.D.
2022 Trial Capacity Award Recipient

Learn more about how Dr. Heiman-Patterson is trying to expand clinical trial access for historically underserved populations in this episode of the Connecting ALS podcast.

Help Boost Clinical Trial Capacity
More trials and more participants mean more opportunities to find new treatments and a cure for ALS. Your support can make a difference.
Print Friendly and PDF